Coleman, Robert <br/><br/>
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.  [electronic resource] 

 -  The Lancet. Oncology  Aug 2014 
 - 997-1006 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(14)70302-X  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bone Density Conservation Agents--therapeutic use<br/>Breast Neoplasms--drug therapy<br/>Chemotherapy, Adjuvant<br/>Confidence Intervals<br/>Diphosphonates--therapeutic use<br/>Disease-Free Survival<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Early Detection of Cancer<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Imidazoles--therapeutic use<br/>Infusions, Intravenous<br/>International Cooperation<br/>Kaplan-Meier Estimate<br/>Middle Aged<br/>Neoplasm Invasiveness--pathology<br/>Neoplasm Staging<br/>Prospective Studies<br/>Survival Rate<br/>Treatment Outcome<br/>Zoledronic Acid